Inhaled Medicines for Targeting Non-Small Cell Lung Cancer
Throughout the years, considerable progress has been made in methods for delivering drugs directly to the lungs, which offers enhanced precision in targeting specific lung regions. Currently, for treatment of lung cancer, the prevalent routes for drug administration are oral and parenteral. These me...
Saved in:
Main Authors: | Arwa Omar Al Khatib (Author), Mohamed El-Tanani (Author), Hisham Al-Obaidi (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Correction: Al Khatib et al. Inhaled Medicines for Targeting Non-Small Cell Lung Cancer. <i>Pharmaceutics</i> 2024, <i>15</i>, 2777
by: Arwa Omar Al Khatib, et al.
Published: (2024) -
Preparation and evaluation of biological activity of ZSM-5 nanoparticles loaded with gefitinib for the treatment of non-small cell lung carcinoma
by: Farah Al-Sahlawi, et al.
Published: (2024) -
Inhalable Anti-EGFR Antibody-Conjugated Osimertinib Liposomes for Non-Small Cell Lung Cancer
by: Apoorva Daram, et al.
Published: (2024) -
Systematic Development and Optimization of Inhalable Pirfenidone Liposomes for Non-Small Cell Lung Cancer Treatment
by: Vineela Parvathaneni, et al.
Published: (2020) -
Inhalable Formulations to Treat Non-Small Cell Lung Cancer (NSCLC): Recent Therapies and Developments
by: Chetna Gupta, et al.
Published: (2022)